Editas Medicine, Inc. (EDIT) investor relations documents from the company's IR site: 6 press releases. Read in-app with summaries. First-party data.
| Published | Type | Document |
|---|---|---|
| 2026-08-05 | Press release | August 5, 2026 Editas Medicine Announces Second Quarter 2026 Results and Business Updates |
| 2026-08-04 | Press release | August 4, 2026 Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. |
| 2026-05-28 | Press release | May 28, 2026 Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference |
| 2026-05-26 | Press release | May 26, 2026 Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and Apo |
| 2026-05-26 | Press release | May 26, 2026 Editas Medicine Announces Proposed Public Offering |
| 2026-05-26 | Press release | May 26, 2026 Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering |
EDIT overview · EDIT earnings · EDIT financials · EDIT KPIs · EDIT ownership · EDIT peers · EDIT filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.